Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)
Clinical trial NCT03713593 · COMPLETED
Trial details
- NCT number
- NCT03713593
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-12-31
- Primary completion
- 2022-06-21
- Enrollment
- 794
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.